Reconstitution of Interleukin-17-Producing T Helper Cells after Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 3, 2013, Pages 357-365

  Bahr, Felix ^a   Wehner, Rebekka ^b   Platzbecker, Uwe ^a   Wermke, Martin ^a   Shayegi, Nona ^a   Middeke, Jan Moritz ^a   Röllig, Christoph ^a   Schetelig, Johannes ^a   Ehninger, Gerhard ^a,b   Schmitz, Marc ^b   Bornhäuser, Martin ^a,b   Tuve, Sebastian ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Allogeneic hematopoietic cell transplantation; Antithymocyte globulin; Graft versus host disease; Interleukin 17; Th17 cells

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; APLASTIC ANEMIA; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; FEMALE; FLOW CYTOMETRY; HELPER CELL; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; MYOFIBROSIS; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; VIRUS REACTIVATION;

ADULT; AGED; ANTILYMPHOCYTE SERUM; BACTERIAL INFECTIONS; CELL PROLIFERATION; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; TH1 CELLS; TH17 CELLS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84873585559     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.11.018     Document Type: Article

References (30)

1. Schetelig J., Kiani A., Schmitz M., et al. T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation. Cancer Immunol Immunother 2005, 54:1043-1058.
2. Shlomchik W.D. Graft-versus-host disease. Nat Rev Immunol 2007, 7:340-352.
3. Socié G., Schmoor C., Bethge W.A., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
4. Socié G., Schmoor C., Bethge W.A., et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011, 117:6375-6382.
5. Murphy W.J., Welniak L.A., Taub D.D., et al. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest 1998, 102:1742-1748.
6. Nikolic B., Lee S., Bronson R.T., et al. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest 2000, 105:1289-1298.
7. Komiyama Y., Nakae S., Matsuki T., et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006, 177:566-573.
8. Hirota K., Yoshitomi H., Hashimoto M., et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007, 204:2803-2812.
9. Chen X., Vodanovic-Jankovic S., Johnson B., et al. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 2007, 110:3804-3813.
10. Kappel L.W., Goldberg G.L., King C.G., et al. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 2009, 113:945-952.
11. Yi T., Chen Y., Wang L., et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2 and Th17 cells in graft-versus-host disease. Blood 2009, 114:3101-3112.
12. Carlson M.J., West M.L., Coghill J.M., et al. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 2009, 113:1365-1374.
13. Iclozan C., Yu Y., Liu C., et al. T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol Blood Marrow Transplant 2010, 16:170-178.
14. Yi T., Zhao D., Lin C.L., et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood 2008, 112:2101-2110.
15. Yu Y., Wang D., Liu C., et al. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. Blood 2011, 118:5011-5020.
16. Dander E., Balduzzi A., Zappa G., et al. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation 2009, 88:1261-1272.
17. Bossard C., Malard F., Arbez J., et al. Plasmacytoid dendritic cells and Th17 immune response contribution in gastrointestinal acute graft-versus-host disease. Leukemia 2012, 26:1471-1474.
18. Broady R., Yu J., Chow V., et al. Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells. Blood 2010, 116:5748-5751.
19. Ratajczak P., Janin A., Peffault de Latour R., et al. Th17/Treg ratio in human graft-versus-host disease. Blood 2010, 116:1165-1171.
20. Dlubek D., Turlej E., Sedzimirska M., et al. Interleukin-17-producing cells increase among CD4+ lymphocytes before overt manifestation of acute graft-versus-host disease. Transplant Proc 2010, 42:3277-3279.
21. Annunziato F., Cosmi L., Santarlasci V., et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007, 204:1849-1861.
22. Peck A., Mellins E.D. Plasticity of T-cell phenotype and function: the T helper type 17 example. Immunology 2010, 129:147-153.
23. Nistala K., Adams S., Cambrook H., et al. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci USA 2010, 107:14751-14756.
24. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007, 21:1387-1394.
25. H17 cells. Nature 2008, 453:1051-1057.
26. O'Keefe S.J., Tamura J., Kincaid R.L., et al. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992, 357:692-694.
27. Zhang C., Zhang J., Yang B., Wu C. Cyclosporin A inhibits the production of IL-17 by memory Th17 cells from healthy individuals and patients with rheumatoid arthritis. Cytokine 2008, 42:345-352.
28. George B., Kerridge I.H., Gilroy N., et al. A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group. Transpl Infect Dis 2012, 14:141-148.
29. Steinman L. Mixed results with modulation of Th-17 cells in human autoimmune diseases. Nat Immunol 2009, 11:41-44.
30. Pidala J., Perez L., Beato F., Anasetti C. Ustekinumab demonstrates activity in glucocorticoid-refractory acute GVHD. Bone Marrow Transplant 2012, 47:747-748.